GSK
GSK to buy liver disease drug for as much as US$2 billion
The drug has the potential to become a best-in-class medicine to treat a form of fatty liver disease
Pfizer sells entire Haleon stake for US$3.24 billion
The total sale represents 7.3% of the issued share capital of Haleon
GSK plans £2 billion share buyback, boosts long-term outlook
The buyback comes after GSK saw earnings per share, excluding some items, at 23.2 pence in the fourth quarter
GSK to buy US cancer biotech IDRx for up to US$1.15 billion
The UK drugmaker will pay US$1 billion upfront for IDRx
GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement
The company admits no wrongdoing or liability and aims to avoid risk of continuing litigation for its long-term interest
GSK wins latest US litigation over Zantac drug saga
British pharmaceutical group GSK on Friday (Aug 16) welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer.
GSK raises annual profit and sales forecast after second quarter beat
BRITISH drugmaker GSK raised its annual earnings and sales forecasts on Wednesday (Jul 31) and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
GSK, Flagship enter multibillion-dollar drug discovery deal
GSK and Flagship Pioneering entered a partnership to develop as many as 10 new drugs in a deal that could pay more than US$7 billion to firms supported by the venture capital biotech.
UK government snubs GSK in favour of rival RSV shot from Pfizer
The decision is a blow to GSK, which is locked in fierce competition with Pfizer to corner the new market to protect against respiratory syncytial virus
GSK plunges as drugmaker must face Zantac cases in Delaware
GSK shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer.
